First blood to Roche in Hemlibra patent fight with Shire

While the ruling doesn’t have a direct bearing on additional challenges outside Japan, Roche has been buoyed by the result. ... Hemlibra has been approved in the US, Europe and Japan to prevent or reduce the frequency of bleeding episodes in patients

Yale Cancer Center joins BMS’ II-ON

Operating under a peer-to-peer approach, the network - which was the first of its kind - has expanded from 10 to 16 sites spanning across North America, Europe, Japan and Australia.

Significant figures

Olaf said that ALIS’second NDA filing will most likely be in Japan due to its big NTM population and the regular frequency of physicians testing for NTM disease in patients.

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 (Next 4)